查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1705487

2025年全球核醫放射性同位素市場報告

Nuclear Medicine Radioisotopes Global Market Report 2025
出版日期: | 出版商: The Business Research Company | 英文 200 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

預計未來幾年核醫放射性同位素的市場規模將強勁成長。預計到 2029 年將成長至 124 億美元，複合年成長率為 8.5%。預測期內的成長可歸因於醫療支出的增加、醫療基礎設施的擴大、對環境永續性的認知的提高、教育宣傳活動和意識提升計劃以及醫療旅遊的成長。預測期內的關鍵趨勢包括新型放射性同位素的開發、生產和供應鏈創新、微流體和實驗室晶片技術、放射性藥物開發中的人工智慧以及奈米技術。

預計未來幾年心血管疾病的盛行率不斷上升將推動核醫放射性同位素市場的成長。心血管疾病包括影響心臟和血管的各種疾病。這些疾病的增加歸因於久坐的生活方式、不良的飲食習慣、肥胖率上升和人口老化。核醫放射性同位素在心血管疾病的診斷、評估和管理中起著至關重要的作用，因為它可以提供關於心臟功能、灌注和組織活力的詳細見解，而這些對於準確的診斷和有效的治療計劃至關重要。例如，2024年9月，英國心血管研究慈善機構英國心臟基金會報告稱，英國約有760萬人患有心臟和循環系統疾病，其中包括約400萬男性和360萬名女性。這些疾病約佔英國所有死亡人數的 27%，每年死亡人數超過 17 萬人，每天約有 480 人死亡——每三分鐘就有一人死亡。因此，心血管疾病發生率的上升正在推動核醫學放射性同位素市場的成長。

核醫放射性同位素市場的關鍵參與者正致力於開發緊湊型低能量迴旋加速器等創新產品，以提高放射性同位素的產量和可用性。緊湊型低能量迴旋加速器是用於產生用於核醫學成像和治療的放射性同位素的小型粒子加速器。例如，2022 年 1 月，IBA 推出了一款新的加速器 Cyclone Key，旨在改善診斷解決方案的取得並實現放射性藥物的內部生產。 Cyclone Key 具有緊湊高效的設計、全自動操作、多種同位素生產能力、易於安裝和操作、水冷、自屏蔽和高性能等特點，用途廣泛且可靠。

目錄

第1章執行摘要

第2章 市場特徵

第3章 市場趨勢與策略

第4章 市場 - 宏觀經濟情景，包括利率、感染疾病、地緣政治、新冠疫情、經濟復甦對市場的影響

第5章 全球成長分析與策略分析框架

  • 全球核醫放射性同位素PESTEL分析（政治、社會、技術、環境、法律因素、促進因素和限制因素）
  • 最終用途產業分析
  • 全球核醫放射性同位素市場：成長率分析
  • 全球核醫放射性同位素市場表現：規模與成長，2019-2024
  • 全球核醫放射性同位素市場預測：2024-2029年及2034年規模與成長
  • 核子醫學放射性同位素的全球總目標市場（TAM）

第6章市場區隔

  • 全球核醫放射性同位素市場：依類型、績效及預測，2019-2024 年、2024-2029 年、2034 年
  • Technetium-99m（Tc-99m）
  • 鉈-201（Tl-201）
  • 碘（I-123）
  • 氟18
  • 銣-82（Rb-82）
  • 碘-131（I-131）
  • 鎦-177（Lu-177）
  • 鐳 223 (Ra-223) 和Alpharadin
  • 其他類型
  • 全球核醫放射性同位素市場：應用、績效及預測（2019-2024 年、2024-2029 年及 2034 年）
  • 腫瘤學
  • 心臟病學
  • 甲狀腺
  • 神經病學
  • 其他用途
  • 全球核醫放射性同位素市場：依最終使用者、績效與預測，2019-2024 年、2024-2029 年、2034 年
  • 醫院
  • 診斷中心
  • 專科診所
  • 教育研究所
  • 其他最終用戶
  • 全球核醫放射性同位素市場Technetium-99m（Tc-99m）細分市場（按類型、性能和預測），2019-2024 年、2024-2029 年、2034 年
  • Technetium酸鈉 Tc-99m
  • Tc-99m MDP（亞甲基二膦酸鹽）
  • Tc-99m HMPAO（六甲基丙胺肟）
  • 全球核醫放射性同位素市場鉈-201（Tl-201）細分市場（按類型、性能和預測），2019-2024 年、2024-2029 年、2034 年
  • 氯化鉈 Tl-201
  • 用於心臟影像成像的鉈-201
  • 全球核醫放射性同位素市場碘-123（I-123）細分市場（按類型、實際及預測），2019-2024 年、2024-2029 年、2034 年
  • 碘123碘化鈉
  • 碘123 碘氟烷（DaTscan）
  • 全球核醫放射性同位素市場氟18細分（按類型）、績效及預測，2019-2024年、2024-2029年、2034年
  • FDG（氟脫氧葡萄糖）F-18
  • 氟化物18用於骨骼成像
  • 全球核醫放射性同位素市場銣-82（Rb-82）細分市場（按類型、性能和預測），2019-2024 年、2024-2029 年、2034 年
  • 用於 PET（正子斷層掃描）影像的 Rb-82
  • Rb-82心臟影像
  • 全球核醫放射性同位素市場碘-131（I-131）細分市場（按類型、性能和預測），2019-2024 年、2024-2029 年、2034 年
  • I-131碘化鈉
  • I-131治療甲狀腺癌
  • I-131治療甲狀腺亢進症
  • 全球核醫放射性同位素市場鎦-177（Lu-177）細分市場（按類型、性能和預測），2019-2024 年、2024-2029 年、2034 年
  • 镥-177-多塔酸鹽
  • Lu-177 在攝護腺癌治療的應用
  • 全球核醫放射性同位素市場鐳-223（Ra-223）細分市場（按類型、性能和預測），2019-2024 年、2024-2029 年、2034 年
  • Ra-223 二氯化物（Zofigo）
  • 全球核醫放射性同位素市場Alpharadin（鐳223阿爾法發射體）細分市場按類型、性能和預測，2019-2024 年、2024-2029 年、2034 年
  • Alpharadin用於治療骨轉移
  • 全球核醫放射性同位素市場，依型別細分，實際及預測，2019-2024 年、2024-2029 年、2034 年
  • Ac-225 用於標靶阿爾法療法 (TAT)
  • Ac-225用於癌症治療
  • 鎵-68（Ga-68）
  • 銅-64（Cu-64）
  • 釔-90（Y-90）

第7章 區域和國家分析

  • 全球核醫放射性同位素市場：依地區、績效及預測，2019-2024 年、2024-2029 年、2034 年
  • 全球核醫放射性同位素市場：依國家/地區、績效及預測，2019-2024 年、2024-2029 年、2034 年

第8章 亞太市場

第9章：中國市場

第10章 印度市場

第11章 日本市場

第12章 澳洲市場

第13章 印尼市場

第14章 韓國市場

第15章 西歐市場

第16章英國市場

第17章 德國市場

第18章 法國市場

第19章：義大利市場

第20章：西班牙市場

第21章 東歐市場

第22章 俄羅斯市場

第23章 北美市場

第24章美國市場

第25章：加拿大市場

第26章 南美洲市場

第27章：巴西市場

第28章 中東市場

第29章：非洲市場

第30章競爭格局與公司概況

  • 核子醫學放射性同位素市場：競爭格局
  • 核子醫學放射性同位素市場：公司簡介
    • Cardinal Health Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
    • Siemens Healthineers AG Overview, Products and Services, Strategy and Financial Analysis
    • GE HealthCare Technologies Overview, Products and Services, Strategy and Financial Analysis
    • BWX Technologies Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 其他大型創新企業

  • Mallinckrodt Pharmaceuticals
  • Bracco Imaging SpA
  • Lantheus Holdings Inc.
  • Curium Pharma
  • Australian Nuclear Science and Technology Organisation（ANSTO）Health
  • Eckert & Ziegler Strahlen
  • NorthStar Medical Radioisotopes
  • NTP Radioisotopes
  • Shine Medical Technologies Inc.
  • Jubilant DraxImage Inc.
  • Isotopia Molecular Imaging Ltd.
  • EczacIbasI-Monrol Nuclear Products
  • International Isotopes Inc.
  • Polatom Sp. z oo
  • Radiomedix Inc

第 32 章全球市場競爭基準化分析與儀表板

第33章 重大併購

第34章近期市場趨勢

第 35 章 高市場潛力國家、細分市場與策略

  • 2029年核醫放射性同位素市場：提供新機會的國家
  • 2029年核醫放射性同位素市場：細分領域帶來新機會
  • 2029年核醫放射性同位素市場：成長策略
    • 基於市場趨勢的策略
    • 競爭對手的策略

第36章 附錄

簡介目錄
Product Code: r30799

Radioactive isotopes, known as nuclear medicine radioisotopes, play crucial roles in diagnosing, treating, and researching diverse medical conditions. These isotopes emit radiation that specialized equipment detects and images, aiding in diagnosis, or administer therapeutic radiation doses to specific tissues. Integral to modern medical practices, nuclear medicine radioisotopes offer essential diagnostic information and therapeutic solutions, thereby enhancing patient outcomes.

Among the primary types of nuclear medicine radioisotopes are technetium-99m (Tc-99m), thallium-201 (Tl-201), iodine (I-123), fluorine-18, rubidium-82 (Rb-82), iodine-131 (I-131), lutetium-177 (Lu-177), radium-223 (Ra-223) and alpharadin, actinium-225 (Ac-225), and others. Technetium-99m (Tc-99m), widely employed in nuclear medicine imaging, facilitates the diagnosis of various medical conditions across oncology, cardiology, thyroid, neurology, and other fields. End users including hospitals, diagnostic centers, specialty clinics, as well as educational and research institutes, benefit from its applications.

The nuclear medicine radioisotopes research report is one of a series of new reports from The Business Research Company that provides nuclear medicine radioisotopes market statistics, including the nuclear medicine radioisotopes industry's global market size, regional shares, competitors with a nuclear medicine radioisotopes market share, detailed nuclear medicine radioisotopes market segments, market trends and opportunities, and any further data you may need to thrive in the nuclear medicine radioisotopes industry. This nuclear medicine radioisotopes market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The nuclear medicine radioisotopes market size has grown strongly in recent years. It will grow from $8.21 billion in 2024 to $8.94 billion in 2025 at a compound annual growth rate (CAGR) of 8.9%. The growth in the historic period can be attributed to discovery of radioactivity, emergence of nuclear medicine, therapeutic applications, clinical research, and patient demand.

The nuclear medicine radioisotopes market size is expected to see strong growth in the next few years. It will grow to $12.4 billion in 2029 at a compound annual growth rate (CAGR) of 8.5%. The growth in the forecast period can be attributed to increasing healthcare spending, expansion of healthcare infrastructure, growing awareness of environmental sustainability, education campaigns and awareness programs and growth in medical tourism. Major trends in the forecast period include development of new radioisotopes, production and supply chain innovations, microfluidics and lab-on-a-chip technology, artificial intelligence in radiopharmaceutical development and nanotechnology.

The increasing prevalence of cardiovascular diseases is expected to drive the growth of the nuclear medicine radioisotope market in the coming years. Cardiovascular diseases encompass a range of conditions that affect the heart and blood vessels. The rise in these diseases can be attributed to sedentary lifestyles, poor dietary habits, higher obesity rates, and aging populations. Nuclear medicine radioisotopes are essential in diagnosing, assessing, and managing cardiovascular diseases by providing detailed insights into cardiac function, perfusion, and tissue viability, which are crucial for accurate diagnoses and effective treatment planning. For example, in September 2024, the British Heart Foundation, a UK-based cardiovascular research charity, reported that approximately 7.6 million people in the UK are affected by heart and circulatory diseases, including around 4 million men and 3.6 million women. These diseases account for about 27% of all deaths in the UK, leading to over 170,000 deaths annually, or approximately 480 deaths per day, which equates to one death every three minutes. As a result, the rising incidence of cardiovascular diseases is fueling the growth of the nuclear medicine radioisotope market.

Key players in the nuclear medicine radioisotopes market are concentrating on developing innovative products such as compact low-energy cyclotrons to enhance the production and availability of radioisotopes, thereby ensuring more efficient and accessible diagnostic and therapeutic options. Compact low-energy cyclotrons are small particle accelerators used to create radioisotopes for medical imaging and treatments in nuclear medicine. For instance, in January 2022, IBA introduced Cyclone Key, a new accelerator designed to provide increased access to diagnostic solutions and enable in-house production of radiopharmaceuticals. Cyclone Key offers features such as a compact and efficient design, fully automated operation, multiple isotope production capabilities, ease of installation and operation, water cooling, self-shielding, and high performance, making it versatile and reliable.

In April 2024, Telix Pharmaceuticals Limited acquired ARTMS, a Canada-based company specializing in novel radioisotope technology. This acquisition aimed to bolster Telix Pharmaceuticals' nuclear medicine capabilities, optimize production procedures, and expand its range of diagnostic and therapeutic radiopharmaceuticals. ARTMS's innovative radioisotope technology holds promise for advancing nuclear medicine applications and addressing the growing demand for radiopharmaceuticals in the diagnosis and treatment of various medical conditions, including cardiovascular diseases.

Major companies operating in the nuclear medicine radioisotopes market are Cardinal Health Inc., Bayer Aktiengesellschaft, Siemens Healthineers AG, GE HealthCare Technologies, BWX Technologies Inc., Mallinckrodt Pharmaceuticals, Bracco Imaging S.p.A., Lantheus Holdings Inc., Curium Pharma, Australian Nuclear Science and Technology Organisation (ANSTO) Health, Eckert & Ziegler Strahlen, NorthStar Medical Radioisotopes, NTP Radioisotopes, Shine Medical Technologies Inc., Jubilant DraxImage Inc., Isotopia Molecular Imaging Ltd., EczacIbasI-Monrol Nuclear Products, International Isotopes Inc., Polatom Sp. z o.o., Radiomedix Inc., Positron Corporation

North America was the largest region in the nuclear medicine radioisotopes market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the nuclear medicine radioisotopes market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the nuclear medicine radioisotopes market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The nuclear medicine radioisotopes market consists of sales of yttrium-90, indium-111, carbon-11, samarium-153, and strontium-89. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Nuclear Medicine Radioisotopes Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on nuclear medicine radioisotopes market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for nuclear medicine radioisotopes ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The nuclear medicine radioisotopes market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Type: Technetium-99m (Tc-99m); Thallium-201 (Tl-201); Iodine (I-123); Fluorine-18; Rubidium-82 (Rb-82); Iodine-131 (I-131); Lutetium-177 (Lu-177); Radium-223 (Ra-223) And Alpharadin; Other Types
  • 2) By Application: Oncology; Cardiology; Thyroid; Neurology; Other Applications
  • 3) By End-User: Hospitals; Diagnostic Centers; Specialty Clinics; Education And Research Institutes; Other End-Users
  • Subsegments:
  • 1) By Technetium-99m (Tc-99m): Sodium Pertechnetate Tc-99m; Tc-99m MDP (Methylene Diphosphonate); Tc-99m HMPAO (Hexamethylpropyleneamine oxime)
  • 2) By Thallium-201 (Tl-201): Thallous Chloride Tl-201; Thallium-201 for Cardiac Imaging
  • 3) By Iodine-123 (I-123): Iodine-123 Sodium Iodide; Iodine-123 Ioflupane (DaTscan)
  • 4) By Fluorine-18: FDG (Fluorodeoxyglucose) F-18; Fluoride-18 For Bone Imaging
  • 5) By Rubidium-82 (Rb-82): Rb-82 For PET (Positron Emission Tomography) Imaging; Rb-82 For Cardiac Imaging
  • 6) By Iodine-131 (I-131): I-131 Sodium Iodide; I-131 For Thyroid Cancer Treatment; I-131 For Hyperthyroidism Treatment
  • 7) By Lutetium-177 (Lu-177): Lu-177-DOTATATE; Lu-177 For Prostate Cancer Treatment
  • 8) By Radium-223 (Ra-223): Ra-223 Dichloride (Xofigo)
  • 9) By Alpharadin (Radium-223 Alpha Emitters): Alpharadin For Bone Metastasis Treatment
  • 10) By Other Types: Ac-225 For Targeted Alpha Therapy (TAT); Ac-225 For Cancer Treatment; Gallium-68 (Ga-68); Copper-64 (Cu-64); Yttrium-90 (Y-90)
  • Companies Mentioned: Cardinal Health Inc.; Bayer AG; Siemens Healthineers AG; GE HealthCare Technologies; BWX Technologies Inc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Nuclear Medicine Radioisotopes Market Characteristics

3. Nuclear Medicine Radioisotopes Market Trends And Strategies

4. Nuclear Medicine Radioisotopes Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Nuclear Medicine Radioisotopes Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Nuclear Medicine Radioisotopes PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Nuclear Medicine Radioisotopes Market Growth Rate Analysis
  • 5.4. Global Nuclear Medicine Radioisotopes Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Nuclear Medicine Radioisotopes Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Nuclear Medicine Radioisotopes Total Addressable Market (TAM)

6. Nuclear Medicine Radioisotopes Market Segmentation

  • 6.1. Global Nuclear Medicine Radioisotopes Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Technetium-99m (Tc-99m)
  • Thallium-201 (Tl-201)
  • Iodine (I-123)
  • Fluorine-18
  • Rubidium-82 (Rb-82)
  • Iodine-131 (I-131)
  • Lutetium-177 (Lu-177)
  • Radium-223 (Ra-223) And Alpharadin
  • Other Types
  • 6.2. Global Nuclear Medicine Radioisotopes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Oncology
  • Cardiology
  • Thyroid
  • Neurology
  • Other Applications
  • 6.3. Global Nuclear Medicine Radioisotopes Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospitals
  • Diagnostic Centers
  • Specialty Clinics
  • Education And Research Institutes
  • Other End-Users
  • 6.4. Global Nuclear Medicine Radioisotopes Market, Sub-Segmentation Of Technetium-99m (Tc-99m), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Sodium Pertechnetate Tc-99m
  • Tc-99m MDP (Methylene Diphosphonate)
  • Tc-99m HMPAO (Hexamethylpropyleneamine oxime)
  • 6.5. Global Nuclear Medicine Radioisotopes Market, Sub-Segmentation Of Thallium-201 (Tl-201), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Thallous Chloride Tl-201
  • Thallium-201 for Cardiac Imaging
  • 6.6. Global Nuclear Medicine Radioisotopes Market, Sub-Segmentation Of Iodine-123 (I-123), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Iodine-123 Sodium Iodide
  • Iodine-123 Ioflupane (DaTscan)
  • 6.7. Global Nuclear Medicine Radioisotopes Market, Sub-Segmentation Of Fluorine-18, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • FDG (Fluorodeoxyglucose) F-18
  • Fluoride-18 For Bone Imaging
  • 6.8. Global Nuclear Medicine Radioisotopes Market, Sub-Segmentation Of Rubidium-82 (Rb-82), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Rb-82 For PET (Positron Emission Tomography) Imaging
  • Rb-82 For Cardiac Imaging
  • 6.9. Global Nuclear Medicine Radioisotopes Market, Sub-Segmentation Of Iodine-131 (I-131), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • I-131 Sodium Iodide
  • I-131 For Thyroid Cancer Treatment
  • I-131 For Hyperthyroidism Treatment
  • 6.10. Global Nuclear Medicine Radioisotopes Market, Sub-Segmentation Of Lutetium-177 (Lu-177), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Lu-177-DOTATATE
  • Lu-177 For Prostate Cancer Treatment
  • 6.11. Global Nuclear Medicine Radioisotopes Market, Sub-Segmentation Of Radium-223 (Ra-223), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Ra-223 Dichloride (Xofigo)
  • 6.12. Global Nuclear Medicine Radioisotopes Market, Sub-Segmentation Of Alpharadin (Radium-223 Alpha Emitters), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Alpharadin For Bone Metastasis Treatment
  • 6.13. Global Nuclear Medicine Radioisotopes Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Ac-225 For Targeted Alpha Therapy (TAT)
  • Ac-225 For Cancer Treatment
  • Gallium-68 (Ga-68)
  • Copper-64 (Cu-64)
  • Yttrium-90 (Y-90)

7. Nuclear Medicine Radioisotopes Market Regional And Country Analysis

  • 7.1. Global Nuclear Medicine Radioisotopes Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Nuclear Medicine Radioisotopes Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Nuclear Medicine Radioisotopes Market

  • 8.1. Asia-Pacific Nuclear Medicine Radioisotopes Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Nuclear Medicine Radioisotopes Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Nuclear Medicine Radioisotopes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Nuclear Medicine Radioisotopes Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Nuclear Medicine Radioisotopes Market

  • 9.1. China Nuclear Medicine Radioisotopes Market Overview
  • 9.2. China Nuclear Medicine Radioisotopes Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Nuclear Medicine Radioisotopes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Nuclear Medicine Radioisotopes Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Nuclear Medicine Radioisotopes Market

  • 10.1. India Nuclear Medicine Radioisotopes Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Nuclear Medicine Radioisotopes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Nuclear Medicine Radioisotopes Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Nuclear Medicine Radioisotopes Market

  • 11.1. Japan Nuclear Medicine Radioisotopes Market Overview
  • 11.2. Japan Nuclear Medicine Radioisotopes Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Nuclear Medicine Radioisotopes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Nuclear Medicine Radioisotopes Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Nuclear Medicine Radioisotopes Market

  • 12.1. Australia Nuclear Medicine Radioisotopes Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Nuclear Medicine Radioisotopes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Nuclear Medicine Radioisotopes Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Nuclear Medicine Radioisotopes Market

  • 13.1. Indonesia Nuclear Medicine Radioisotopes Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Nuclear Medicine Radioisotopes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Nuclear Medicine Radioisotopes Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Nuclear Medicine Radioisotopes Market

  • 14.1. South Korea Nuclear Medicine Radioisotopes Market Overview
  • 14.2. South Korea Nuclear Medicine Radioisotopes Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Nuclear Medicine Radioisotopes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Nuclear Medicine Radioisotopes Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Nuclear Medicine Radioisotopes Market

  • 15.1. Western Europe Nuclear Medicine Radioisotopes Market Overview
  • 15.2. Western Europe Nuclear Medicine Radioisotopes Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Nuclear Medicine Radioisotopes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Nuclear Medicine Radioisotopes Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Nuclear Medicine Radioisotopes Market

  • 16.1. UK Nuclear Medicine Radioisotopes Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Nuclear Medicine Radioisotopes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Nuclear Medicine Radioisotopes Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Nuclear Medicine Radioisotopes Market

  • 17.1. Germany Nuclear Medicine Radioisotopes Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Nuclear Medicine Radioisotopes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Nuclear Medicine Radioisotopes Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Nuclear Medicine Radioisotopes Market

  • 18.1. France Nuclear Medicine Radioisotopes Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Nuclear Medicine Radioisotopes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Nuclear Medicine Radioisotopes Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Nuclear Medicine Radioisotopes Market

  • 19.1. Italy Nuclear Medicine Radioisotopes Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Nuclear Medicine Radioisotopes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Nuclear Medicine Radioisotopes Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Nuclear Medicine Radioisotopes Market

  • 20.1. Spain Nuclear Medicine Radioisotopes Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Nuclear Medicine Radioisotopes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Nuclear Medicine Radioisotopes Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Nuclear Medicine Radioisotopes Market

  • 21.1. Eastern Europe Nuclear Medicine Radioisotopes Market Overview
  • 21.2. Eastern Europe Nuclear Medicine Radioisotopes Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Nuclear Medicine Radioisotopes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Nuclear Medicine Radioisotopes Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Nuclear Medicine Radioisotopes Market

  • 22.1. Russia Nuclear Medicine Radioisotopes Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Nuclear Medicine Radioisotopes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Nuclear Medicine Radioisotopes Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Nuclear Medicine Radioisotopes Market

  • 23.1. North America Nuclear Medicine Radioisotopes Market Overview
  • 23.2. North America Nuclear Medicine Radioisotopes Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Nuclear Medicine Radioisotopes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Nuclear Medicine Radioisotopes Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Nuclear Medicine Radioisotopes Market

  • 24.1. USA Nuclear Medicine Radioisotopes Market Overview
  • 24.2. USA Nuclear Medicine Radioisotopes Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Nuclear Medicine Radioisotopes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Nuclear Medicine Radioisotopes Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Nuclear Medicine Radioisotopes Market

  • 25.1. Canada Nuclear Medicine Radioisotopes Market Overview
  • 25.2. Canada Nuclear Medicine Radioisotopes Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Nuclear Medicine Radioisotopes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Nuclear Medicine Radioisotopes Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Nuclear Medicine Radioisotopes Market

  • 26.1. South America Nuclear Medicine Radioisotopes Market Overview
  • 26.2. South America Nuclear Medicine Radioisotopes Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Nuclear Medicine Radioisotopes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Nuclear Medicine Radioisotopes Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Nuclear Medicine Radioisotopes Market

  • 27.1. Brazil Nuclear Medicine Radioisotopes Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Nuclear Medicine Radioisotopes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Nuclear Medicine Radioisotopes Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Nuclear Medicine Radioisotopes Market

  • 28.1. Middle East Nuclear Medicine Radioisotopes Market Overview
  • 28.2. Middle East Nuclear Medicine Radioisotopes Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Nuclear Medicine Radioisotopes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Nuclear Medicine Radioisotopes Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Nuclear Medicine Radioisotopes Market

  • 29.1. Africa Nuclear Medicine Radioisotopes Market Overview
  • 29.2. Africa Nuclear Medicine Radioisotopes Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Nuclear Medicine Radioisotopes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Nuclear Medicine Radioisotopes Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Nuclear Medicine Radioisotopes Market Competitive Landscape And Company Profiles

  • 30.1. Nuclear Medicine Radioisotopes Market Competitive Landscape
  • 30.2. Nuclear Medicine Radioisotopes Market Company Profiles
    • 30.2.1. Cardinal Health Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Siemens Healthineers AG Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. GE HealthCare Technologies Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. BWX Technologies Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Nuclear Medicine Radioisotopes Market Other Major And Innovative Companies

  • 31.1. Mallinckrodt Pharmaceuticals
  • 31.2. Bracco Imaging S.p.A.
  • 31.3. Lantheus Holdings Inc.
  • 31.4. Curium Pharma
  • 31.5. Australian Nuclear Science and Technology Organisation (ANSTO) Health
  • 31.6. Eckert & Ziegler Strahlen
  • 31.7. NorthStar Medical Radioisotopes
  • 31.8. NTP Radioisotopes
  • 31.9. Shine Medical Technologies Inc.
  • 31.10. Jubilant DraxImage Inc.
  • 31.11. Isotopia Molecular Imaging Ltd.
  • 31.12. EczacIbasI-Monrol Nuclear Products
  • 31.13. International Isotopes Inc.
  • 31.14. Polatom Sp. z o.o.
  • 31.15. Radiomedix Inc

32. Global Nuclear Medicine Radioisotopes Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Nuclear Medicine Radioisotopes Market

34. Recent Developments In The Nuclear Medicine Radioisotopes Market

35. Nuclear Medicine Radioisotopes Market High Potential Countries, Segments and Strategies

  • 35.1 Nuclear Medicine Radioisotopes Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Nuclear Medicine Radioisotopes Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Nuclear Medicine Radioisotopes Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer